REGENXBIO Sees Positive Results For Macular Degeneration Therapy
By Karen Roman REGENXBIO Inc. (Nasdaq: RGNX), a clinical-stage biotechnology company, said its subretinal treatment of age-related macular degeneration showed improved vision in patients. Two years of data were published in The Lancet regarding the ongoing trials of ABBV-RGX-314, its...